Recurrent Ovarian Serous Adenocarcinoma
2 clinical trials · Condition
◉ Watch Recurrent Ovarian Serous Adenocarcinoma
| Record | Firm | Date |
|---|---|---|
| Testing the Addition of an Immunotherapy Drug, Tremelimumab, to the PARP Inhibition Drug, Olaparib, for Recurrent Ovarian, Fallopian Tube or Peritoneal Cancer (NCT04034927) | National Cancer Institute (NCI) | 2019-12-04 |
Track Recurrent Ovarian Serous Adenocarcinoma automatically
Every clearance here is in the API, with alerts when new ones post.